Peptide Guide + Calculator
Retatrutide Reconstitution Calculator & Guide
GLP-1 / GIP / Glucagon Triple Receptor Agonist
Retatrutide is an investigational triple hormone receptor agonist being studied for obesity, type 2 diabetes, and related cardiometabolic conditions. This page explains how Retatrutide works, current clinical-trial research, commonly reported side effects, comparisons with Tirzepatide and Semaglutide, and educational reconstitution math.
Evidence Snapshot
Retatrutide research at a glance
Standardized regulatory and evidence context so research compounds, investigational drugs, and approved medications are not treated as if they have the same level of human evidence.
Primary mechanism
Triple GIP, GLP-1, and glucagon receptor agonist.
WADA context
Non-approved substance — S0 may applyHuman intervention evidence
Peer-reviewed Phase 2 evidence and positive company-reported Phase 3 TRIUMPH results are available, but retatrutide remains investigational and has no FDA-approved product as of 2026.
Human biology evidence
Human trials show substantial metabolic and weight effects consistent with activity across three hormone-receptor systems.
Key takeaway
The strongest investigational metabolic compound on the site, but it should remain clearly separated from approved semaglutide and tirzepatide products.
Evidence labels describe the research base and regulatory context; they are not treatment, dosing, or use recommendations. Review dates describe the last BACToBasics source check for this evidence summary. Anti-doping rules can change and should be verified with the applicable authority.
Retatrutide Reconstitution Calculator
Enter the vial amount, liquid volume, and amount you want to calculate. BACToBasics will automatically calculate concentration, liquid volume, and U-100 syringe-unit equivalents.
Loading calculator...
Calculator values are educational math inputs only. They are not recommended preparation amounts, doses, or use protocols.
Retatrutide Reconstitution Math
Reconstitution math starts with the amount contained in the vial and the liquid volume used in the calculation. Dividing the vial amount by the liquid volume gives the resulting concentration.
Example vial amount
10 mg
| Liquid Volume | Calculation | Concentration |
|---|---|---|
| 1 mL | 10 mg ÷ 1 mL | 10 mg/mL |
| 2 mL | 10 mg ÷ 2 mL | 5 mg/mL |
| 3 mL | 10 mg ÷ 3 mL | 3.3333 mg/mL |
This table demonstrates concentration math only. The liquid volumes shown are examples for comparison and are not preparation recommendations.
More Reconstitution Tools
Need to compare different liquid volumes or convert between mg, mcg, mL, and U-100 units? Use the dedicated BACToBasics calculator tools.
What is Retatrutide?
Retatrutide is an investigational medication developed by Eli Lilly. It is often described as a triple receptor agonist because a single molecule activates glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. It is being studied as a potential treatment for obesity, type 2 diabetes, and several obesity-related health conditions.
How does Retatrutide work?
Retatrutide combines activity at three metabolic hormone receptors. GLP-1 and GIP signaling are associated with appetite, satiety, glucose regulation, and insulin response, while glucagon-receptor activity adds another metabolic pathway that may influence energy balance and substrate utilization. Researchers are studying whether combining all three mechanisms can produce effects that differ from medications targeting only one or two of these pathways.
Current Retatrutide research status
Retatrutide remains investigational and is not currently an FDA-approved medication. Eli Lilly has reported positive results from multiple Phase 3 trials and has said it plans to submit Retatrutide for U.S. regulatory approval in the first quarter of 2027. Additional studies are evaluating cardiovascular and kidney outcomes and other obesity-related conditions.
What have Retatrutide clinical trials shown?
Clinical trials have reported substantial average weight reductions in participants receiving Retatrutide. In Lilly's Phase 3 TRIUMPH-1 trial, participants assigned to the 12mg target dose lost an average of 28.3% of their starting body weight at 80 weeks. Other Phase 3 trials have also reported substantial weight loss in adults with obesity and type 2 diabetes or established cardiovascular disease. Some recent Phase 3 results remain company-reported topline data while full peer-reviewed publications continue to follow.
Retatrutide vs Tirzepatide
Tirzepatide activates GLP-1 and GIP receptors, while Retatrutide activates GLP-1, GIP, and glucagon receptors. The additional glucagon-receptor activity is the major mechanistic difference between the two. Tirzepatide is already available as an FDA-approved prescription medication for specific indications, while Retatrutide remains investigational.
Retatrutide vs Semaglutide
Semaglutide primarily activates the GLP-1 receptor. Tirzepatide adds GIP-receptor activity, while Retatrutide adds both GIP and glucagon-receptor activity alongside GLP-1. This is why the three medications are often described as single-, dual-, and triple-receptor agonists respectively, although their clinical effects cannot be predicted solely by counting the receptors they target.
Side effects reported in Retatrutide trials
The most commonly reported adverse effects in Retatrutide clinical trials have been gastrointestinal, including nausea, diarrhea, constipation, and vomiting. Decreased appetite has also been reported. Phase 3 studies have additionally reported dysesthesia, which refers to unusual or altered skin sensations, in some participants. Earlier research also observed dose-related increases in heart rate. Safety continues to be evaluated as the clinical-development program progresses.
Retatrutide and appetite
Reduced appetite and increased satiety are frequently discussed effects of Retatrutide and other incretin-based therapies. Clinical weight-loss outcomes reflect multiple metabolic mechanisms rather than appetite suppression alone, and individual responses can vary substantially.
Retatrutide reconstitution math
Reconstitution calculations depend on the labeled amount in a vial and the volume of liquid used. For example, purely as a math example, a 10mg vial combined with 2mL of liquid produces a concentration of 5mg per mL. BACToBasics uses these values only to demonstrate concentration, volume, and U-100 syringe-unit calculations and does not provide a Retatrutide dosing or preparation protocol.
Research Retatrutide vs clinical-trial Retatrutide
Retatrutide used in Eli Lilly clinical trials is an investigational pharmaceutical product supplied within controlled research studies. Products advertised online as research Retatrutide are not the same as an FDA-approved commercial Retatrutide product, because no such approved product currently exists. Product identity, purity, sterility, concentration, and manufacturing quality cannot be assumed from an online label.
Explore more about Retatrutide
14 linksComparisons, research records, development tracking, blends, and related guides are available here when you want to go deeper.
Explore more about Retatrutide
14 linksComparisons, research records, development tracking, blends, and related guides are available here when you want to go deeper.
Compare Retatrutide
Direct comparison pages are selected from the indexable BACToBasics comparison catalog and update automatically as that catalog grows.
Cagrilintide vs Retatrutide
Compare Cagrilintide, Retatrutide using the same evidence dataset.
Open →
ComparisonCagriSema vs Retatrutide
Compare CagriSema, Retatrutide using the same evidence dataset.
Open →
ComparisonMariTide vs Retatrutide
Compare MariTide, Retatrutide using the same evidence dataset.
Open →
ComparisonMazdutide vs Retatrutide
Compare Mazdutide, Retatrutide using the same evidence dataset.
Open →
Research, updates & development
Jump from the guide into the public update timeline, compound-specific research records, and clinical-development tracker without searching again.
Retatrutide research & development updates
Open the public timeline of sourced research records and material development changes tracked by BACToBasics.
Open →
ResearchRetatrutide research sources
Open 2 curated research records for Retatrutide.
Open →
DevelopmentRetatrutide clinical development
Phase 3 · Active development. TRIUMPH Phase 3 program; positive TRIUMPH-1 results reported in 2026.
Open →
Related peptide guides
Related guides are ranked from shared comparison pages, shared blend pages, and peptide category rather than a hand-maintained link list.
Semaglutide guide & calculator
Metabolic & Weight Loss · GLP-1 Receptor Agonist
Open →
Peptide guideTirzepatide guide & calculator
Metabolic & Weight Loss · GLP-1 / GIP Dual Receptor Agonist
Open →
Peptide guideAOD-9604 guide & calculator
Metabolic & Weight Loss · Modified Human Growth Hormone Fragment
Open →
Peptide guideCagrilintide guide & calculator
Metabolic & Weight Loss · Long-Acting Amylin Analog
Open →
Relevant glossary concepts
Definitions are matched against the guide's structured title, subtitle, description, and educational sections.
FDA-Approved
A status indicating that the FDA has approved a specific drug product for one or more labeled uses after reviewing the required evidence and manufacturing information.
Open →
GlossaryMilliliter (mL)
A metric unit of liquid volume equal to one-thousandth of a liter.
Open →
GlossaryAgonist
A molecule that binds to a receptor and activates signaling through that receptor.
Open →
Retatrutide FAQ
Tap a question to expand only the answer you want to read.
Is Retatrutide FDA-approved?
No. Retatrutide remains investigational. Eli Lilly has reported positive Phase 3 results and has said it plans to submit Retatrutide for U.S. regulatory approval in the first quarter of 2027.
Why is Retatrutide called a triple agonist?
Retatrutide is called a triple agonist because one molecule activates three hormone receptors: GLP-1, GIP, and glucagon receptors.
How is Retatrutide different from Tirzepatide?
Tirzepatide activates GLP-1 and GIP receptors. Retatrutide activates those same two receptor systems plus the glucagon receptor, making it a triple receptor agonist.
How is Retatrutide different from Semaglutide?
Semaglutide primarily targets the GLP-1 receptor, while Retatrutide activates GLP-1, GIP, and glucagon receptors.
How much weight loss has Retatrutide shown in trials?
Results vary by study population and target dose. In Lilly's Phase 3 TRIUMPH-1 trial, participants assigned to the 12mg target dose lost an average of 28.3% of starting body weight at 80 weeks. Trial averages should not be interpreted as a prediction of an individual's result.
What are the most common Retatrutide side effects?
The most commonly reported adverse effects in clinical trials have included nausea, diarrhea, constipation, vomiting, and reduced appetite. Altered skin sensations, sometimes described as dysesthesia, have also been reported in Phase 3 studies.
Can Retatrutide increase heart rate?
Earlier clinical research observed dose-dependent increases in heart rate that peaked during treatment and later declined. Retatrutide's cardiovascular safety continues to be studied in the broader Phase 3 development program.
Is Retatrutide currently available as a prescription?
Retatrutide is not currently an FDA-approved prescription medication. Eli Lilly's Retatrutide remains an investigational product being evaluated through clinical trials and regulatory development.
Is research Retatrutide sold online the same as Lilly's Retatrutide?
An online product labeled Retatrutide should not be assumed to be equivalent to the investigational pharmaceutical product used in Eli Lilly clinical trials. Identity, concentration, purity, sterility, and manufacturing quality may differ.
How do you calculate Retatrutide reconstitution concentration?
For concentration math, divide the labeled amount in the vial by the liquid volume. For example, 10mg divided by 2mL equals 5mg per mL. This is a mathematical relationship and not a recommendation for how a product should be prepared.
Can the BACToBasics calculator handle Retatrutide math?
Yes. The calculator can use a labeled vial amount and liquid volume to calculate concentration, equivalent liquid volume, U-100 syringe units, and approximate amounts per vial. The tool provides educational math rather than dosing recommendations.
Sources & References
3 sourcesOpen the references when you want to inspect the research and regulatory sources behind this guide.
Sources & References
3 sourcesOpen the references when you want to inspect the research and regulatory sources behind this guide.
Company-reported Phase 3 results announced in May 2026, including efficacy and safety findings through 80 weeks.
Phase 3 randomized controlled trial evaluating Retatrutide in adults with obesity or overweight.
Peer-reviewed Phase 2 obesity trial: Triple-Hormone-Receptor Agonist Retatrutide for Obesity. DOI: 10.1056/NEJMoa2301972.
BACToBasics provides educational information and math tools only. This content is not medical advice, dosing advice, injection instruction, or a recommendation to use any peptide or medication.